GERNON CORPORATION INVESTORS: Contact Robbins LLP to Lead the Class Action Against GERN

Core Viewpoint - A class action has been filed against Geron Corporation for allegedly misleading investors about the launch and growth potential of its drug Rytelo, leading to a significant decline in stock price following disappointing financial results [1][2][3]. Group 1: Company Overview - Geron Corporation is a commercial-stage biopharmaceutical company focused on blood cancer treatment, with its primary product being a telomerase inhibitor called imetelstat, marketed as Rytelo [1]. Group 2: Allegations and Financial Impact - The complaint alleges that Geron failed to disclose critical factors affecting Rytelo's market performance, including seasonality, competition, and lack of awareness, which contributed to a failure to meet growth expectations [2]. - On February 26, 2025, Geron reported that Rytelo's growth had flattened, attributing this to seasonality, competition, and monitoring requirements, resulting in a stock price drop from $2.37 to$1.61, a decline of approximately 32.07% in one day [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Geron, with a deadline to file as lead plaintiff by May 12, 2025. Participation is not required to be eligible for recovery [4]. Group 4: Legal Representation - Robbins LLP, a firm specializing in shareholder rights litigation, represents the class action on a contingency fee basis, meaning shareholders incur no fees or expenses [5].